Migraine Patients with Comorbid Disorders and Their Management

  • Stefan EversEmail author
Part of the Headache book series (HEAD)


A 45-year-old female patient was admitted to a headache clinic because she experienced an increase of frequency in her known migraine without aura attacks. Since puberty, she suffered from menstrual migraine attacks with a duration of 3–4 days. The attacks were accompanied by nausea, photophobia, and phonophobia. In the first years, she took paracetamol or acetylsalicylic acid to treat the attacks which was of limited success; often 5–10 tablets were needed during the headache period. After introduction of the triptans, she switched to sumatriptan 100 mg tablets which gave her relief for a whole day; later she took also zolmitriptan 5 mg. She never was put on a short-term prophylaxis or other prophylactic treatment.


Valproic Acid Migraine Attack Beta Blocker Migraine Patient Migraine With Aura 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Suggested Reading

  1. 1.
    Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB (2013) Psychiatric comorbidities of episodic and chronic migraine. J Neurol 260:1960–1969PubMedCrossRefGoogle Scholar
  2. 2.
    Cianchetti C, Pruna D, Ledda M (2013) Epileptic seizures and headache/migraine: a review of types of association and terminology. Seizure 22:679–685PubMedCrossRefGoogle Scholar
  3. 3.
    Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sandor P (2009) EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol 16:968–981PubMedCrossRefGoogle Scholar
  4. 4.
    Katsarava Z, Weimar C (2010) Migraine and stroke. J Neurol Sci 299:42–44PubMedCrossRefGoogle Scholar
  5. 5.
    Linde M, Mulleners WM, Chronicle EP, McCrory DC (2013) Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev (6):CD010608Google Scholar
  6. 6.
    Mehle ME (2012) Migraine and allergy: a review and clinical update. Curr Allergy Asthma Rep 12:240–245PubMedCrossRefGoogle Scholar
  7. 7.
    Nappi RE, Nappi G (2012) Neuroendocrine aspects of migraine in women. Gynecol Endocrinol 28(Suppl 1):37–41PubMedCrossRefGoogle Scholar
  8. 8.
    Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R (2005) The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 45:144–152PubMedCrossRefGoogle Scholar
  9. 9.
    Sathe S (2013) Migraine and neurogenetic disorders. Curr Pain Headache Rep 17:360PubMedCrossRefGoogle Scholar
  10. 10.
    Schwedt TJ (2009) The migraine association with cardiac anomalies, cardiovascular disease, and stroke. Neurol Clin 27:513–523PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Stovner LJ et al (2013) A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia 34:523–532PubMedCrossRefGoogle Scholar
  12. 12.
    Tronvik E et al (2003) Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289:65–69PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Department of NeurologyKrankenhaus LindenbrunnCoppenbrüggeGermany

Personalised recommendations